VCL-HB01
phase 2 Vical
Last updated:
| Developer | Vical |
|---|---|
| Platform | DNA |
| HSV target | HSV-2 |
| Approach | therapeutic |
| Phase | phase 2 |
| Status | A Phase 2 trial in adults with symptomatic genital HSV-2 was completed in 2018 with no results posted on the registry; as of the 2026-09-27 registry search, no record naming VCL-HB01 has an ongoing status. |
| Trials | NCT02030301 , NCT02837575 |
VCL-HB01 is a therapeutic HSV-2 DNA vaccine sponsored by Vical, tested in adults who already have symptomatic HSV-2 infection. It was studied in a phase 1/2 dose-escalation trial with 165 actual enrolments, completed in 2016, and a phase 2 trial with 261 actual enrolments, completed in 2018. Neither trial has results posted on the registry, and as of the 2026-09-27 registry search no record naming VCL-HB01 has an ongoing status.
What it is
VCL-HB01 is a DNA vaccine that its registry records describe as a therapeutic vaccine for HSV-2, sponsored by Vical. Both of its registered trials enrolled adults who already had symptomatic HSV-2 infection.
Where it stands
NCT02030301 was a randomized, double-blind, placebo-controlled, dose-escalation phase 1/2 trial in symptomatic HSV-2-seropositive adults. It listed VCL-HB01, VCL-HM01 and PBS as interventions. It enrolled 165 participants (actual count), was completed in 2016, and has no results posted on the registry. NCT02837575 was a randomized, double-blind, placebo-controlled phase 2 trial of VCL-HB01 against phosphate-buffered saline in adults with symptomatic genital HSV-2 infection. It enrolled 261 participants (actual count), was completed in 2018, and has no results posted on the registry. A ClinicalTrials.gov search on 2026-09-27 for records naming VCL-HB01 returned these 2 records, and none had an ongoing status.
What this does and doesn’t mean
Completing a phase 2 trial shows the vaccine was tested, not that it worked; neither registry record has results posted. The sources here contain no published safety or efficacy results for VCL-HB01.
Registry snapshot
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
- Registry status
- Completed
- Phase
- phase 1/2
- Enrollment
- 165 (actual)
- Lead sponsor
- Vical
- Started
- Dec 2013
- Primary completion
- Jun 2015
Registry record last updated Feb 27, 2019.
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
- Registry status
- Completed
- Phase
- phase 2
- Enrollment
- 261 (actual)
- Lead sponsor
- Vical
- Started
- Sep 2016
- Primary completion
- Apr 2018
Registry record last updated Feb 27, 2019.
Sources
- ClinicalTrials.gov registry search for VCL-HB01 (searched 2026-09-27)
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults (NCT02030301)
- A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection (NCT02837575)